Skip to main content
. 2019 Jan 1;143(1):e20180902. doi: 10.1542/peds.2018-0902

TABLE 5.

Univariable Analysis of Patient, Provider, and Practice Characteristics and Adverse Events During Intubations Performed in the NICU

Factor TIAEs Severe Desaturations
Any TIAE (n = 361) No TIAE (n = 1648) P Severe Desaturation (n = 938) No Severe Desaturation (n = 1012) P
Patient current wt, g, median (IQR) 1300 (782–2595) 1940 (1000–3100) <.001 1600 (900–3000) 1925 (1034–3050) .01
Gestational age at birth, wk, median (IQR) 27 (25–32) 29 (25–35) <.001 28 (25–34) 30 (26–36) <.001
Patient postnatal age, d, median (IQR) 13 (1–42) 13 (1–50) .35 20 (2–56) 6 (1–44) <.001
Indication, n (%)
 Ventilation failure 134 (37) 625 (38) .78 358 (38) 390 (39) .87
 Oxygen failure 114 (32) 515 (31) .90 307 (33) 311 (31) .34
 Frequent apnea and bradycardia events 95 (26) 302 (18) .001 206 (22) 176 (17) .01
 Surfactant administration 70 (19) 293 (18) .47 142 (15) 209 (21) .002
 Reintubation after unplanned extubation 48 (13) 204 (12) .63 129 (14) 115 (11) .11
 Upper airway obstruction 26 (7) 84 (5) .11 59 (6) 48 (5) .13
 Procedure 17 (5) 197 (12) <.001 87 (9) 120 (12) .06
 Unstable hemodynamics 14 (4) 26 (2) .005 19 (2) 18 (2) .69
First providera
 Pediatric resident 60 of 187 (32%) 239 of 861 (28%) .47 169 of 509 (33%) 126 of 513 (25%) .003
 NICU fellow 102 of 187 (55%) 507 of 861 (59%) 269 of 509 (53%) 323 of 513 (63%)
 NICU attending 25 of 187 (13%) 115 of 861 (13%) 71 of 509 (14%) 64 of 513 (12%)
Video laryngoscopeb 26 of 192 (14%) 387 of 990 (39%) <.001 192 of 573 (34%) 214 of 593 (36%) .36
Sedative premedication 198 (55%) 1086 (66%) <.001 634 (68%) 632 (62%) .02
Paralytic premedicationc 95 of 341 (28%) 850 of 1589 (53%) <.001 430 of 904 (48%) 503 of 969 (52%) .06
No. attempts, median (IQR) 3 (2–4) 1 (1–2) <.001 2 (1–3) 1 (1–2) <.001

IQR, interquartile range.

a

First provider analysis only includes intubations with resident, fellow, or attending providers.

b

Video laryngoscope analysis only includes sites that report any video laryngoscope use.

c

Analysis of paralytic medication only includes sites that reported any paralytic use.